TWI298256B - Chloride channel opener - Google Patents

Chloride channel opener Download PDF

Info

Publication number
TWI298256B
TWI298256B TW091119830A TW91119830A TWI298256B TW I298256 B TWI298256 B TW I298256B TW 091119830 A TW091119830 A TW 091119830A TW 91119830 A TW91119830 A TW 91119830A TW I298256 B TWI298256 B TW I298256B
Authority
TW
Taiwan
Prior art keywords
group
compound
alkyl
carbon number
composition
Prior art date
Application number
TW091119830A
Other languages
English (en)
Chinese (zh)
Inventor
Ueno Ryuji
Cuppoletti John
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26980134&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI298256(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Application granted granted Critical
Publication of TWI298256B publication Critical patent/TWI298256B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TW091119830A 2001-08-31 2002-08-30 Chloride channel opener TWI298256B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31591701P 2001-08-31 2001-08-31
US37210402P 2002-04-15 2002-04-15

Publications (1)

Publication Number Publication Date
TWI298256B true TWI298256B (en) 2008-07-01

Family

ID=26980134

Family Applications (1)

Application Number Title Priority Date Filing Date
TW091119830A TWI298256B (en) 2001-08-31 2002-08-30 Chloride channel opener

Country Status (11)

Country Link
US (2) US7064148B2 (https=)
EP (1) EP1420794B1 (https=)
JP (2) JP4786866B2 (https=)
AR (1) AR036391A1 (https=)
AU (1) AU2002330747B2 (https=)
BR (1) BR0212233A (https=)
CA (1) CA2458471C (https=)
MX (1) MXPA04002006A (https=)
NZ (1) NZ531503A (https=)
TW (1) TWI298256B (https=)
WO (1) WO2003030912A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE387204T1 (de) * 2001-05-18 2008-03-15 Sucampo Ag Zusammensetzung mit induzierendem kathartischen effekt
AR037524A1 (es) * 2001-11-14 2004-11-17 Sucampo Ag Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
TWI263505B (en) * 2001-11-19 2006-10-11 Sucampo Ag Pharmaceutical composition comprising a C1C-2 channel opener
NZ539582A (en) * 2002-10-23 2007-07-27 Sucampo Ag Prostaglandin compounds for the treatment of obesity
EP1575596B1 (en) * 2002-12-27 2016-06-22 Sucampo AG Derivatives of prostaglandins for treating irritable bowel syndrome and/or functional dyspepsia
DE602004030245D1 (de) * 2003-07-03 2011-01-05 Sucampo Ag Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner
TWI495471B (zh) 2003-08-12 2015-08-11 R Tech Ueno Ltd 促進毛髮生長之組成物及方法
TWI387454B (zh) * 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
ES2714198T3 (es) * 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
RU2468800C2 (ru) * 2005-04-12 2012-12-10 Сукампо Аг Комбинированное применение производного простагландина и ингибитора протонового насоса для лечения желудочно-кишечных заболеваний
CA2642744C (en) * 2006-02-28 2015-02-24 Sucampo Ag Method and composition for treating chronic obstructive pulmonary disease
JP5427029B2 (ja) * 2006-09-06 2014-02-26 スキャンポ・アーゲー 消化管の重炭酸分泌を促進するための方法および組成物
US20080207759A1 (en) * 2007-02-27 2008-08-28 Sucampo Ag Method for protecting mitochondria
US20090012165A1 (en) * 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
US20090030072A1 (en) * 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
CA2702094C (en) 2007-10-10 2018-05-01 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
CN101318948B (zh) * 2008-04-01 2011-04-27 上海天伟生物制药有限公司 鲁比前列酮晶体、其制备方法及用途
US20110034424A1 (en) * 2009-06-30 2011-02-10 Sucampo Ag Method for the long term nsaid use
RS53234B (sr) * 2009-08-07 2014-08-29 Scipharm Sàrl Kompozicija za lečenje cistične fibroze
AU2010295464B2 (en) * 2009-09-18 2015-11-26 Merck Sharp & Dohme Corp. Use of opioid receptor antagonist for gastrointestinal tract disorders
LT2672957T (lt) * 2011-02-07 2017-02-10 Scipharm Sarl Naujoji kompozicija, skirta cistinės fibrozės gydymui
EP2717855A4 (en) 2011-06-07 2014-11-12 Parion Sciences Inc Methods of Treatment
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
WO2014085655A1 (en) * 2012-11-29 2014-06-05 Indiana University Research And Technology Corporation Dielectric electrolyte measurement device
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
US20150057351A1 (en) * 2013-08-22 2015-02-26 Sucampo Ag Method for treating neuropathic pain
US20160228403A1 (en) 2013-10-04 2016-08-11 Tohoku University Agent for preventing or ameliorating renal dysfunction
JP6957610B2 (ja) 2016-10-06 2021-11-02 スキャンポ・アーゲーＳｕｃａｍｐｏ ＡＧ 医薬品用途のための多層ビーズ
CN110267670B (zh) 2016-10-20 2023-08-15 表飞鸣制药株式会社 对肠道的离子跨细胞转运体的作用剂、氯离子通道活化剂、肾脏疾病的预防或治疗剂或者排便促进剂
US10457623B1 (en) * 2018-07-13 2019-10-29 Chirogate International Inc. Process for the preparation of Lubiprostone and intermediates thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE43462B1 (en) * 1975-06-23 1981-03-11 Pfizer Substituted tetranorprostaglandins
US4091207A (en) * 1976-04-22 1978-05-23 Pfizer Inc. Prostaglandin intermediate including oxathio heterocyclic ring
IT1098350B (it) * 1977-07-28 1985-09-07 Upjohn Co Derivati prostaglandinici
JPS6033429B2 (ja) * 1980-04-28 1985-08-02 小野薬品工業株式会社 プロスタグランジン類似化合物
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
JPH0681728B2 (ja) * 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
ES2051862T3 (es) * 1987-10-02 1994-07-01 Ueno Seiyaku Oyo Kenkyujo Kk Un metodo para producir un medicamento que tiene un efecto catartico.
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
CA2030344C (en) 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
JPH0791192B2 (ja) * 1989-11-22 1995-10-04 株式会社上野製薬応用研究所 ガス交換機能不全処置剤
TW224942B (https=) 1990-04-04 1994-06-11 Adka Ueno Kk
ATE174221T1 (de) * 1990-05-01 1998-12-15 R Tech Ueno Ltd Behandlung von pankreaskrankheit mit 15-keto- prostaglandin e-derivaten
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
US6015828A (en) 1996-05-31 2000-01-18 Cuppoletti; John Chemical modification of chloride channels as a treatment for cystic fibrosis and other diseases
WO1997047595A1 (en) 1996-06-10 1997-12-18 R-Tech Ueno, Ltd. Endothelin antagonist
CA2274670C (en) * 1997-10-13 2011-04-12 R-Tech Ueno, Ltd. 15-keto prostaglandins as portal hypertension inhibitors
AU739343B2 (en) * 1997-11-28 2001-10-11 Sucampo Ag Endothelin antagonist
CA2333038C (en) * 1998-05-25 2008-12-02 Taisho Pharmaceutical Co., Ltd. Sleep-inducing preparation
TWI284535B (en) 2000-03-24 2007-08-01 Sucampo Ag Apoptosis inhibitor
EP1267883B1 (en) 2000-04-06 2009-06-17 Sucampo AG Bile secretion promoting composition for liver transplantation containing a 15-keto-prostaglandin
TWI302100B (en) 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
FR2829293B1 (fr) * 2001-08-31 2003-11-14 Centre Nat Rech Scient Memoire moleculaire et son procede de fabrication

Also Published As

Publication number Publication date
JP5568021B2 (ja) 2014-08-06
JP2011102313A (ja) 2011-05-26
AU2002330747B2 (en) 2007-07-19
JP2005504836A (ja) 2005-02-17
CA2458471C (en) 2012-07-31
BR0212233A (pt) 2004-10-05
CA2458471A1 (en) 2003-04-17
AR036391A1 (es) 2004-09-08
MXPA04002006A (es) 2004-06-07
US7064148B2 (en) 2006-06-20
WO2003030912A1 (en) 2003-04-17
NZ531503A (en) 2006-01-27
US7253295B2 (en) 2007-08-07
JP4786866B2 (ja) 2011-10-05
EP1420794A1 (en) 2004-05-26
EP1420794B1 (en) 2017-12-27
US20060122411A1 (en) 2006-06-08
US20030130352A1 (en) 2003-07-10

Similar Documents

Publication Publication Date Title
TWI298256B (en) Chloride channel opener
AU2002330747A1 (en) Prostaglandin analogs as chloride channel opener
CN102014921A (zh) 用于调节干细胞生长的含前列腺素的组合物
TW209170B (https=)
TWI288639B (en) Treatment of emphysema using RARgamma selective retinoid agonists
EP0366279A2 (en) Ocular hypotensive agents
TW200418491A (en) Pharmaceutical composition for treating abdominal discomfort
US8530519B2 (en) Method for promoting upper gastrointestinal bicarbonate secretion
US7459583B2 (en) Method for providing a cathartic effect
JP2002534389A (ja) 女性性機能障害の治療のための方法および組成物
TW205508B (https=)
US20080207759A1 (en) Method for protecting mitochondria
JP2563158B2 (ja) ノナテトラエン酸誘導体
HK1252353A1 (zh) 治疗精神分裂症的方法
TW201102070A (en) Pharmaceutical composition for modulating claudin mediated functions
TWI281395B (en) Hydroxyeicosatetraenoic acid analogs, the composition thereof and use thereof in the manufacture of a medicament for treating dry eye and other disorders requiring the wetting of the eye in mammals
US20160120840A1 (en) Method and composition for treating nonerosive reflux disease
EP3008171A1 (en) Method for suppressing tumorigenicity of stem cells
US20120277299A1 (en) Method for modulating ion transporter
CA2870252A1 (en) Method for treating irritable bowel syndrome with diarrhea
US20060004107A1 (en) Method for designing a pharmaceutical compound specific to a desired receptor, a designed compound thereby, and pharmaceutical compositions containing the same
US20140212441A1 (en) Pharmaceutical composition for inflammatory diseases, allergic diseases and autoimmune diseases

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent